Zhejiang Tenchen Controls(603085.SH) subsidiary has received a notice of appointing for the automotive seat frame project.
Tiancheng Automation (603085.SH) announced that its wholly-owned subsidiary Wuhan Tiancheng Automation Automotive Seat Co., Ltd. (referred to as "Wuhan Tiancheng") recently received a notice of designation for the passenger car seat frame project from a well-known joint venture automotive company (referred to as "customer"). Wuhan Tiancheng has been identified as the designated supplier for the passenger car seat frame project of this customer. According to the customer's plan, the project is expected to start mass production in July 2027, with a project lifecycle of 5 years, and an expected total of 315,000 passenger cars to be equipped with the seat frames during the project period.
Zhejiang Tenchen Controls (603085.SH) announced that its wholly-owned subsidiary, Wuhan Zhejiang Tenchen Controls Automotive Seat Co., Ltd. (referred to as "Wuhan Tiancheng"), recently received a notice of designation from a well-known joint venture automotive company (referred to as "the customer") for the passenger car seat frame project. Wuhan Tiancheng has been identified as the designated supplier for a specific passenger car seat frame project for the customer. According to the customer's plan, the project is expected to begin mass production in July 2027, with a project lifecycle of 5 years, and an estimated total volume of 315,000 passenger cars during the project period.
Related Articles
On May 14, TRADEGO (08017) spent 1.2473 million Hong Kong dollars to repurchase 1 million shares.
ZHOU HEI YA (01458) spent 997,100 Hong Kong dollars to repurchase 633,500 shares on May 14th.
Sichuan Biokin Pharmaceutical (688506.SH): SI-B036 bispecific antibody injection approved to conduct clinical trials in advanced solid tumors.
On May 14, TRADEGO (08017) spent 1.2473 million Hong Kong dollars to repurchase 1 million shares.
ZHOU HEI YA (01458) spent 997,100 Hong Kong dollars to repurchase 633,500 shares on May 14th.
Sichuan Biokin Pharmaceutical (688506.SH): SI-B036 bispecific antibody injection approved to conduct clinical trials in advanced solid tumors.
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
11/05/2026
